← Back to Search

CAR T-cell Therapy

BMS-986393 for Multiple Myeloma (QUINTESSENTIAL Trial)

Phase 2
Research Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 5 years
Awards & highlights


This trial aims to test how well BMS-986393 works and how safe it is for people with multiple myeloma that has come back or not responded to previous treatment.

Who is the study for?
This trial is for adults with multiple myeloma that has come back or hasn't responded to treatment. Specific details about who can join are not provided, but typically participants need to meet certain health standards and have a history of the condition being studied.Check my eligibility
What is being tested?
The study is testing BMS-986393, which is a CAR T cell therapy targeting GPRC5D, a protein often found on myeloma cells. The goal is to see how effective and safe this therapy is in treating patients whose multiple myeloma has relapsed or resisted other treatments.See study design
What are the potential side effects?
While specific side effects for BMS-986393 aren't listed here, common ones for CAR T cell therapies include flu-like symptoms, fatigue, fever, difficulty breathing, and changes in blood pressure. Some may experience more severe immune reactions.

QUINTESSENTIAL Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am fully active or can carry out light work.
I have been diagnosed with multiple myeloma according to IMWG standards.
I have undergone 4 types of treatments for my multiple myeloma, including at least 3 different therapy lines.
My myeloma has worsened despite treatment.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Area under the concentration-time curve (AUC)
BOR of complete response (CR) [including stringent complete response sCR]
BOR of partial response (PR) or better
+20 more


1Treatment groups
Experimental Treatment
Group I: BMS-986393Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyLead Sponsor
14 Previous Clinical Trials
1,577 Total Patients Enrolled
5 Trials studying Multiple Myeloma
308 Patients Enrolled for Multiple Myeloma
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,506 Previous Clinical Trials
3,369,380 Total Patients Enrolled
72 Trials studying Multiple Myeloma
25,137 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

In how many distinct locations is this investigation currently being conducted?

"A total of 25 sites are currently active for patient enrollment in this trial, including but not limited to the University of Kansas Medical Center in Kansas City, Roswell Park Cancer Institute in Buffalo, and Moffitt Cancer Center in Tampa."

Answered by AI

Are there ongoing efforts to actively enroll participants for this clinical trial?

"As per clinicaltrials.gov, this investigation is not presently seeking participants. This study was first listed on April 15th, 2024 and last revised on February 28th, 2024. Despite the current lack of patient recruitment for this trial, there are currently 807 other studies actively seeking eligible individuals to participate."

Answered by AI

Has the drug BMS-986393 received approval from the FDA?

"Based on the current phase of this trial, our team at Power rates BMS-986393 with a safety score of 2. This reflects available safety data but lacks evidence regarding efficacy."

Answered by AI
~100 spots leftby Oct 2026